YARROW BIOSCIENCE, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
YARROW BIOSCIENCE, INC. (YARW) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2021-03-04
- YARROW BIOSCIENCE, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- YARROW BIOSCIENCE, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2019 was $3.00K.
- YARROW BIOSCIENCE, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2018 was -$74.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 |
| 2019-12-31 | $3.00K 10-K · filed 2021-03-04 |
| 2018-12-31 | -$74.00K 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |